has reached a significant milestone with its Optilume ® Drug-Coated Balloon (DCB). The groundbreaking treatment for recurrent bulbar urethral strictures has had its five-year follow-up data from ...

Plymouth-based medical device maker Urotronic is ramping up clinical research on its Optilume drug-coated balloon to treat men with narrowed urethras, accelerating the data-gathering process for ...

Now drug-coated balloons have entered the picture. With the Optilume BPH catheter system, urologists inflate a balloon to split the lobes of the prostate. A second balloon can further separate the ...

The results underscore the long-term durability and safety of the Optilume ® Drug-Coated Balloon (DCB) as a minimally invasive treatment for recurrent anterior urethral strictures in men.

In the Optilume procedure, an uncoated balloon catheter is used to open a passage between the lateral lobes of the prostate (anterior commissurotomy). A second balloon, coated with the ...

Approved by the US Food and Drug Administration in 2023, the Optilume BPH devices uses balloons to dilate the anterior commissure of the prostate, which connects the two lobes of the gland ...

GIE Medical aims to translate Urotronic’s Optilume drug-coated balloon approach into a treatment for benign strictures of the gastrointestinal tract, including narrowings of the esophagus ...

Plymouth-based med-tech company Urotronic Inc. is slated to trade hands in a $255 million deal. Last week, New Hampshire-based Laborie Medical Technologies Inc. announced it has inked a deal to ...

The results underscore the long-term durability and safety of the Optilume ® Drug-Coated Balloon (DCB) as a minimally invasive treatment for recurrent anterior urethral strictures in men. The study ...